Glenmark Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Glenmark Pharmaceuticals has a total shareholder equity of ₹84.5B and total debt of ₹15.6B, which brings its debt-to-equity ratio to 18.5%. Its total assets and total liabilities are ₹152.4B and ₹67.9B respectively. Glenmark Pharmaceuticals's EBIT is ₹17.8B making its interest coverage ratio 4.9. It has cash and short-term investments of ₹18.2B.
Key information
18.5%
Debt to equity ratio
₹15.62b
Debt
| Interest coverage ratio | 4.9x |
| Cash | ₹18.20b |
| Equity | ₹84.45b |
| Total liabilities | ₹67.90b |
| Total assets | ₹152.35b |
Recent financial health updates
Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?
Dec 17
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Recent updates
Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?
Dec 17Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now
Oct 26This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Financial Position Analysis
Short Term Liabilities: GLENMARK's short term assets (₹90.3B) exceed its short term liabilities (₹61.8B).
Long Term Liabilities: GLENMARK's short term assets (₹90.3B) exceed its long term liabilities (₹6.1B).
Debt to Equity History and Analysis
Debt Level: GLENMARK has more cash than its total debt.
Reducing Debt: GLENMARK's debt to equity ratio has reduced from 59.7% to 18.5% over the past 5 years.
Debt Coverage: GLENMARK's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: GLENMARK's interest payments on its debt are well covered by EBIT (4.9x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 05:57 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Glenmark Pharmaceuticals Limited is covered by 55 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Ganeshram Jayaraman | Avendus Spark |